Researchers have identified proteins with the potential to prevent heart failure, thanks to work originating at ICGEB.
12 September 2022: Nature Italy features the new genetic method that has identified three factors that shield cardiac cells from the effects of infarction.
As published on 31 August in Science Translational Medicine, research collaboration at ICGEB, the University of Trieste and Forcefield Therapeutics, King’s College London has led to the identification of three proteins which have the potential to prevent heart failure after heart attack.
The paper published in Science Translational Medicine describes three proteins which have been shown to preserve heart function following acute myocardial infarction (heart attack) via a unique combination of cardioprotective mechanisms in preclinical proof-of-concept studies.
Led by Mauro Giacca, Professor of Cardiovascular Sciences at King’s College London, supported by the British Heart Foundation, researchers developed an innovative technology called FunSel that searched for proteins that could protect heart cells against the rapid cell death that typically occurs following a heart attack.
Forcefield Therapeutics, a pioneer of best-in-class therapeutics to retain heart function via protection of cardiomyocytes, launched in 2022, is undertaking the development work to enable clinical trials in patients in the future. The work originated at the International Centre for Genetic Engineering and Biology (ICGEB) and the University of Trieste, Italy.